Article Information
History
- January 27, 2022.
Article Versions
- Version 1 (November 8, 2021 - 17:07).
- Version 2 (November 10, 2021 - 09:43).
- Version 3 (November 19, 2021 - 15:40).
- You are viewing Version 4, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Selin Somersan-Karakaya1,a,*,
- Eleftherios Mylonakis2,a,
- Vidya P. Menon3,
- Jason C. Wells4,
- Shazia Ali1,
- Sumathi Sivapalasingam1,b,
- Yiping Sun1,
- Rafia Bhore1,
- Jingning Mei1,
- Jutta Miller1,
- Lisa Cupelli1,
- Andrea T. Hooper1,
- Jennifer D. Hamilton1,
- Cynthia Pan1,
- Viet Pham1,
- Yuming Zhao1,
- Romana Hosain1,
- Adnan Mahmood1,
- John D. Davis1,
- Kenneth C. Turner1,
- Yunji Kim1,
- Amanda Cook1,
- Bari Kowal1,
- Yuhwen Soo1,
- A. Thomas DiCioccio1,
- Gregory P. Geba1,
- Neil Stahl1,
- Leah Lipsich1,b,
- Ned Braunstein1,
- Gary A. Herman1,
- George D. Yancopoulos1,
- David M. Weinreich1,
- COVID-19 Phase 2/3 Hospitalized Trial Team
- 1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
- 2Brown University, Providence, RI, USA
- 3NYC Health + Hospitals/Lincoln, The Bronx, NY, USA
- 4The Oregon Clinic, Portland, OR, USA
- ↵*Correspondence to:
Selin Somersan-Karakaya, MD, Email: selin.somersan{at}regeneron.com.
↵a S. S-K. and E. M. contributed equally.
Posted January 27, 2022.
Casirivimab and imdevimab for the treatment of hospitalized patients with COVID-19
